Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial

Alexander V. Louie*, Erik van Werkhoven, Hanbo Chen, Egbert F. Smit, Marinus A. Paul, Joachim Widder, Harry J. M. Groen, Ben E. E. M. van den Borne, Katrien De Jaeger, Ben J. Slotman, Suresh Senan

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

71 Citations (Scopus)

Abstract

We report quality of life and indirect costs from patient reported outcomes from the ROSEL randomized control trial comparing stereotactic ablative radiotherapy (SABR, also known as stereotactic body radiotherapy or SBRT) versus surgical resection for medically operable stage IA non-small cell lung cancer. ROSEL closed prematurely after accruing and randomizing 22 patients. This exploratory analysis found the global health related quality of life and indirect costs to be significantly favorable and cheaper, with SABR. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)44-48
Number of pages5
JournalRadiotherapy and Oncology
Volume117
Issue number1
DOIs
Publication statusPublished - Oct-2015

Keywords

  • Lung cancer
  • Quality of life
  • Patient reported outcomes
  • SABR
  • SBRT
  • Surgery
  • QUALITY-OF-LIFE
  • BODY RADIOTHERAPY
  • CLINICAL-TRIALS
  • INSTRUMENT
  • SURVIVAL
  • THERAPY
  • QLQ-C30

Cite this